Maxim Group Issues Pessimistic Forecast for Plus Therapeutics (NASDAQ:PSTV) Stock Price

Plus Therapeutics (NASDAQ:PSTV) had its price objective trimmed by Maxim Group from $4.00 to $3.00 in a research report sent to investors on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts also recently weighed in on PSTV. D Boral Capital downgraded Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 5th. Ascendiant Capital Markets boosted their price target on Plus Therapeutics from $20.00 to $20.50 and gave the stock a “buy” rating in a research report on Thursday, June 5th. HC Wainwright lowered their price target on Plus Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a research report on Friday, June 27th. Wall Street Zen raised Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, D. Boral Capital reissued a “hold” rating and set a $9.00 price target on shares of Plus Therapeutics in a research report on Wednesday, June 25th. Three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Plus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $8.88.

Plus Therapeutics Stock Performance

PSTV opened at $0.4836 on Monday. Plus Therapeutics has a 52-week low of $0.1634 and a 52-week high of $2.3099. The firm has a market capitalization of $29.25 million, a PE ratio of -0.22 and a beta of 0.67. The business’s 50-day simple moving average is $0.43 and its 200 day simple moving average is $0.67.

Plus Therapeutics (NASDAQ:PSTV) last released its earnings results on Thursday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.08. The company had revenue of $1.39 million for the quarter, compared to the consensus estimate of $1.08 million. On average, research analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Plus Therapeutics stock. Virtu Financial LLC purchased a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 40,030 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 0.24% of Plus Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.